Patents by Inventor Stephen Gillies

Stephen Gillies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11045533
    Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: June 29, 2021
    Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
  • Publication number: 20210032315
    Abstract: The invention relates to humanized and de-immunized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of monoclonal antibodies of the invention to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the antibodies of the invention.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 4, 2021
    Inventors: Jens-Ulrich RAHFELD, Stephen Gillies, Thore HETTMANN, Stephan SCHILLING, Martin KLEINSCHMIDT
  • Publication number: 20200138922
    Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
    Type: Application
    Filed: January 16, 2020
    Publication date: May 7, 2020
    Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
  • Patent number: 10603367
    Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: March 31, 2020
    Assignee: Probiodrug AG
    Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
  • Patent number: 8420087
    Abstract: The invention provides a compound comprising a target specific portion and an effector portion wherein the target specific portion comprises or consists of a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody and the effector portion comprises or consists of interleukin-12, or a functional fragment or variant thereof, characterized in the monoclonal antibody having specificity for oncofoetal fibronectin binds to a region of oncofoetal fibronectin other than the ED-B region. The invention further provides nucleic acids encoding the compounds of the invention, and the use of such compounds in medicine, e.g. in the treatment of cancer.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: April 16, 2013
    Assignees: Antisoma Research Limited, EMD Serono Research Center, Inc.
    Inventors: Stephen Gillies, Kin-Ming Lo, Yan Lan, Rakesh Verma
  • Patent number: 7615217
    Abstract: The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: November 10, 2009
    Assignee: Merck Patent GmbH
    Inventors: Stephen Gillies, Francis J. Carr, Jones Tim, Graham Carter, Anita Hamilton, Stephen Williams, Marian Hanlon, John Watkins, Matthew Baker, Jeffrey C. Way
  • Publication number: 20090088561
    Abstract: Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis of antibody isotypes that normally bind Fc receptors. The fusion proteins of the present invention may also contain a functional domain capable of binding an immunoglobulin protection receptor.
    Type: Application
    Filed: October 2, 2008
    Publication date: April 2, 2009
    Applicant: Merck Patent GmbH
    Inventors: Stephen Gillies, Kin-Ming Lo, Yan Lan, John Wesolowski
  • Publication number: 20080025947
    Abstract: Methods directed to enhancing the effectiveness of IL-2 in stimulating the immune system is disclosed. According to one method, an antagonist directed against the CD25 subunit of the high-affinity IL-2 receptor complex is administered in conjunction with IL-2. The CD25 antagonist may be an anti-CD25 antibody. According to another method, an anti-IL-2 antibody is administered in conjunction with IL-2. In another method, a mutant IL-2 with diminished ability to bind the CD25 subunit of the high-affinity IL-2 receptor complex is administered. In another method, an CD4 antagonist is administered in conjunction with IL-2 in order to stimulate the immune system.
    Type: Application
    Filed: July 5, 2007
    Publication date: January 31, 2008
    Applicant: Merck Patent GmbH
    Inventors: Stephen Gillies, Kin-Ming Lo, Yan Lan
  • Publication number: 20070269435
    Abstract: The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules.
    Type: Application
    Filed: March 12, 2007
    Publication date: November 22, 2007
    Inventors: Stephen Gillies, Francis Carr, Jones Tim, Graham Carter, Anila Hamilton, Stephen Williams, Marian Hanlon, John Watkins, Matthew Baker, Jeffrey Way
  • Publication number: 20070258944
    Abstract: The invention relates to protein complexes and fusion proteins including at least two different cytokine molecules. The protein complexes and fusion proteins may further include a targeting moiety such as a region of an immunoglobulin. Methods of using the protein complexes and fusion proteins are also disclosed.
    Type: Application
    Filed: November 20, 2006
    Publication date: November 8, 2007
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Stephen Gillies, Kin-Ming Lo
  • Publication number: 20070202103
    Abstract: The invention provides a compound comprising a target specific portion and an effector portion wherein the target specific portion comprises or consists of a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody and the effector portion comprises or consists of interleukin-12, or a functional fragment or variant thereof, characterised in the monoclonal antibody having specificity for oncofoetal fibronectin binds to a region of oncofoetal fibronectin other than the ED-B region. The invention further provides nucleic acids encoding the compounds of the invention, and the use of such compounds in medicine, e.g. in the treatment of cancer.
    Type: Application
    Filed: January 5, 2005
    Publication date: August 30, 2007
    Inventors: Stephen Gillies, Kin-Ming Lo, Yan Lan, Rakesh Verma
  • Publication number: 20070178098
    Abstract: The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.
    Type: Application
    Filed: December 29, 2006
    Publication date: August 2, 2007
    Applicant: Merck Patent GmbH
    Inventors: Jeffrey Way, Stephen Gillies, Kin-Ming Lo, Yuan Liu
  • Publication number: 20070104689
    Abstract: The present invention provides compositions and methods that elicit an immune response against diseased cells. In particular, the present invention provides compositions and methods for the presentation of a peptide related to survivin on antigen-presenting cells. Presentation of the peptide leads to an immune response in a mammal against cells such as tumor cells overexpressing survivin.
    Type: Application
    Filed: September 26, 2006
    Publication date: May 10, 2007
    Applicant: Merck Patent GmbH
    Inventors: Stephen Gillies, Thore Hettmann, Pascal Stein, Stephan Klinz
  • Publication number: 20070059282
    Abstract: The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.
    Type: Application
    Filed: November 15, 2006
    Publication date: March 15, 2007
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Stephen Gillies, Kin-Ming Lo, Susan Qian
  • Patent number: 7189830
    Abstract: The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules.
    Type: Grant
    Filed: February 18, 2002
    Date of Patent: March 13, 2007
    Assignee: Merck Patent GmbH
    Inventors: Stephen Gillies, Francis J. Carr, Jones Tim, Graham Carter, Anita Hamilton, Stephen Williams, Marian Hanlon, John Watkins, Matthew Baker, Jeffrey C. Way
  • Publication number: 20070036751
    Abstract: The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.
    Type: Application
    Filed: September 26, 2006
    Publication date: February 15, 2007
    Inventors: Holger Lode, Ralph Reisfeld, David Cheresh, Stephen Gillies
  • Publication number: 20070036752
    Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
    Type: Application
    Filed: October 16, 2006
    Publication date: February 15, 2007
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Stephen Gillies, Pascal Stein, Kin-Ming Lo
  • Publication number: 20070009538
    Abstract: A homodimeric protein of the invention has angiogenesis inhibiting activity. The homodimeric protein consists of two identical fusion proteins bound together as a homodimer. Each fusion protein comprises an immunoglobulin Fc region and a first target protein linked to the immunoglobulin Fc region. The first target protein has an angiogenesis inhibiting activity of angiostatin or endostatin, and is selected from the group consisting of a plasminogen fragment and a collagen XVIII fragment. The immunoglobulin Fc region comprises a hinge region, a CH2 region, and a CH3 region.
    Type: Application
    Filed: June 27, 2006
    Publication date: January 11, 2007
    Inventors: Kin-Ming Lo, Yue Li, Stephen Gillies
  • Publication number: 20060263856
    Abstract: Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.
    Type: Application
    Filed: July 19, 2006
    Publication date: November 23, 2006
    Applicant: EMD Lexigen Research Center Corp.
    Inventors: Stephen Gillies, Jeffrey Way, Kin-Ming Lo
  • Publication number: 20060228332
    Abstract: Disclosed are Fc-interferon-beta (Fc-IFN-?) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-? fusion proteins include variants of the interferon-beta (IFN-?) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.
    Type: Application
    Filed: June 27, 2005
    Publication date: October 12, 2006
    Applicant: MERCK Patent GmbH
    Inventors: Stephen Gillies, Nigel Watkins, Matthew Baker, Kin-Ming Lo, Steven Degon